Celldex Therapeutics to Present CDX-011 Clinical Data at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium
NEEDHAM, Mass.–(BUSINESS WIRE)– Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the Company’s first antibody-drug conjugate (ADC) product candidate, CDX-011 (formerly CR011-vcMMAE), for the treatment of locally advanced or metastatic breast cancer will be the subject of a poster presentation at the 2009 San Antonio Breast Cancer Symposium. Poster #6096, “A Phase I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer,” will include safety, tolerability and efficacy data. It is scheduled for presentation during Poster Session 6 in Exhibit Halls A-B from 7:00 a.m. to 9:00 a.m. CST on Sunday, December 13, 2009 at the Henry B. Gonzalez Convention Center in San Antonio, TX.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.